Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Santana-Davila, A. Szabo, C. Arce-Lara, C. Williams, M. Kelley, J. Whittle (2014)
Cisplatin versus Carboplatin-Based Regimens for the Treatment of Patients with Metastatic Lung Cancer. An Analysis of Veterans Health Administration DataJournal of Thoracic Oncology, 9
P. Bonomi, Kyungmann Kim, D. Fairclough, D. Cella, J. Kugler, E. Rowinsky, Michael Jiroutek, David Johnson (2000)
Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 3
(2006)
Paclitaxelcarboplatin alone or with bevacizumab for non-small-cell lung cancer
A. Sandler, R. Gray, M. Perry, J. Brahmer, J. Schiller, A. Dowlati, R. Lilenbaum, David Johnson (2006)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.The New England journal of medicine, 355 24
R. Rosell, U. Gatzemeier, D. Betticher, U. Keppler, H. Macha, Robert Pirker, P. Berthet, J. Breau, P. Lianes, M. Nicholson, A. Ardizzoni, A. Chemaissani, Jan Bogaerts, Gilles Gallant (2002)
Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial.Annals of oncology : official journal of the European Society for Medical Oncology, 13 10
A. Chougule, K. Prabhash, V. Noronha, A. Joshi, A. Thavamani, P. Chandrani, Pawan Upadhyay, S. Utture, S. Desai, N. Jambhekar, A. Dutt (2013)
Frequency of EGFR Mutations in 907 Lung Adenocarcioma Patients of Indian EthnicityPLoS ONE, 8
C. Liam, M. Wahid, P. Rajadurai, Y. Cheah, T. Ng (2013)
Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma in Malaysian PatientsJournal of Thoracic Oncology, 8
Yuankai Shi, J. Au, S. Thongprasert, S. Srinivasan, C. Tsai, M. Khoa, K. Heeroma, Y. Itoh, G. Cornelio, Pan‐Chyr Yang (2014)
A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)Journal of Thoracic Oncology, 9
D. Reich, K. Thangaraj, N. Patterson, A. Price, L. Singh (2009)
Reconstructing Indian Population HistoryNature, 461
S. D’Angelo, M. Pietanza, M. Johnson, Gregory Riely, V. Miller, C. Sima, M. Zakowski, V. Rusch, M. Ladanyi, M. Kris (2011)
Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15
A. Ardizzoni, L. Boni, M. Tiseo, F. Fossella, J. Schiller, M. Paesmans, D. Radosavljević, A. Paccagnella, P. Zatloukal, P. Mazzanti, D. Bisset, R. Rosell (2007)
Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.Journal of the National Cancer Institute, 99 11
LETTERS TO THE EDITOR 3. Sandler A, Gray R, Perry MC, et al. Paclitaxel– As we know, good-designed ran- Cisplatin or carboplatin alone or with bevacizumab for domized clinical trials provide strong non–small-cell lung cancer. New England Carboplatin for evidence that may change the current Journal of Medicine 2006;355:2542–2550. treatment pattern. Rosell and colleagues 4. Rosell R, Gatzemeier U, Betticher DC, et al. Advanced Non–Small- Phase III randomised trial comparing pacli- conducted direct comparison of pacli- taxel/carboplatin with paclitaxel/cisplatin in taxel/carboplatin versus paclitaxel/cispl- Cell Lung Cancer? patients with advanced non-small-cell lung atin in advanced NSCLC. The baseline cancer: a cooperative multinational trial. Ann patient’s characteristics and follow-up Oncol 2002;13:1539–1549. To the Editor: therapy were well balanced between 5. Ardizzoni A, Boni L, Tiseo M, et al. We have read with great inter- XXX Cisplatin- versus carboplatin-based chemo- the two treatment arms. The overall therapy in first-line treatment of advanced est the article “Cisplatin versus response rate in the two arms of pacli- non-small-cell lung cancer: an individual Carboplatin-Based Regimens for the taxel/carboplatin and paclitaxel/cis- patient data meta-analysis. J Natl Cancer Inst Treatment of Patients with Metastatic platin was 28% and 25%, respectively, 2007;99:847–857. Lung Cancer. An Analysis of Veterans which was similar. However, patients Health Administration Data” reported received paclitaxel/cisplatin had the sig- XXX by Santana-Davila and colleagues in nificantly longer median survival (9.8 Journal of Thoracic oncology (May EGFR Mutations in months) than paclitaxel/carboplatin (8.2 2014). We are impressed that the months). This is confirmed by an indi- Asian Patients with authors presented a great retrospec- 5 vidual patient data meta-analysis. In tive study with competent data and Advanced Lung patients with non-squamous histology, accurate statistical analysis. However, cisplatin-based chemotherapy prolonged Adenocarcinoma selection bias obviously existed in the survival in comparison to carboplatin- study, as they stated in the discussion based chemotherapy (hazard ratio = part. First, although the study sample 1.12, 95% confidence interval = 1.01– To the Editor: is large enough, which included 4352 1.23), but not in squamous histology. In 1 We congratulate Shi et al for patients, only 291 (6.7%) patients in our opinion, there are enough evidences their prospective multinational, epide- the cisplatin group. Second, the inho- to support use of cisplatin in advanced miological study of epidermal growth mogeneity of combined chemothera- NSCLC, especially in non-squamous factor receptor (EGFR) mutations in peutic agents may affect the overall histology. In our daily clinical practice, patients from Asia with newly diag- survival. Approximately 30% of for eligible patients with non-squamous nosed advanced lung adenocarcinoma patients treated with cisplatin were NSCLC, we would like to recommend (PIONEER study) which showed that administered with etoposide, whereas cisplatin preferentially. 51.4% of tumors from 1450 patients only 1.7% of patients in the carbo- had a positive EGFR mutation status. platin group. Third, bevacizumab was Although the frequency of EGFR muta- Xiaoli Sun, MD used more in carboplatin group (5.9%) tions was 50% or higher for patients Department of Radiotherapy than in cisplatin group (0.7%). When of East Asian ethnicities (Vietnamese, added to paclitaxel/carboplatin, it 64.2%; Thai, 53.8%; Chinese, 51.8%, Yulong Zheng, MD can improve survival in previously and Filipino, 50.0%), it was significantly Department of Medical Oncology untreated patients with advanced non- lower for Indian patients (21.9%). Our The First Affiliated Hospital squamous non–small-cell lung cancer study on Malaysian patients who were (NSCLC). In addition, the authors did of Zhejiang University of three major ethnicities, ie, Chinese, not mention the post-study treatment. Hangzhou, China Malay, and Indian, showed that 39.5% During the last decade, many advances of tumors from 812 patients with have been made in the treatment of REFERENCES advanced adenocarcinoma were EGFR advanced NSCLC, e.g., targeted ther- 1. Santana-Davila R, Szabo A, Arce-Lara mutation positive. The frequency of apy. Further treatment after first-line C, Williams CD, Kelley MJ, Whittle J. EGFR mutations was not significantly chemotherapy may also impact on Cisplatin versus carboplatin-based regimens different between our Chinese (40.8% overall survival. for the treatment of patients with meta- of 517 patients), Malay (37.2% of 239 static lung cancer. an analysis of Veterans Health Administration data. J Thorac Oncol 2014;9:702–709. Address for correspondence: Xiaoli Sun, MD, 2. Bonomi P, Kim K, Fairclough D, et al. Address for correspondence: Chong-Kin Liam, Department of Radiotherapy, The First Comparison of survival and quality of life MBBS, MRCP, Department of Medicine, Affiliated Hospital of Zhejiang University, in advanced non–small-cell lung cancer Faculty of Medicine, University of Malaya, 79 Qingchun Road, Hangzhou, Zhejiang, patients treated with two dose levels of pacli- 50603 Kuala Lumpur, Malaysia. E-mail: 310003, China. E-mail: fox006@163.com taxel combined with cisplatin versus eto- liamck@ummc.edu.my Copyright © 2014 by the International Association poside with cisplatin: Results of an Eastern Copyright © 2014 by the International Association for the Study of Lung Cancer Cooperative Oncology Group trial. Journal of for the Study of Lung Cancer ISSN: 1556-0864/14/0909-0e70 ISSN: 1556-0864/14/0909-0e70 Clinical Oncology 2000;18:623–623. Journal of Thoracic Oncology • Volume 9, Number 9, September 2014 e70
Journal of Thoracic Oncology – Wolters Kluwer Health
Published: Sep 1, 2014
You can share this free article with as many people as you like with the url below! We hope you enjoy this feature!
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.